# AHA: Pelacarsen cuts lipoprotein(a) levels but does not lower risk for major adverse cardiovascular events

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-aha-pelacarsen-lipoproteina-major-adverse.html) · 2026-11-12 · Medicine
Page: https://themorning.science/story/aha-pelacarsen-cuts-lipoprotein-a-levels-but-does-not-lower-risk-for-major-adver-7f3658b271ec269e
Kind: research · Impact: medium

## In brief

- Pelacarsen, a monthly antisense oligonucleotide, lowers lipoprotein(a) levels in adults with preexisting cardiovascular disease.
- The drug does not reduce the occurrence of major adverse cardiovascular events in the same group.
- The findings were published online on Nov. 7 and reported by the American Heart Association.

## Why it matters

Lowering lipoprotein(a) alone did not translate into fewer major cardiovascular events in this population, which bears on whether this biomarker is a valid treatment target.

## Timeline

- 2026-11-07: Study of pelacarsen published online

## Coverage

- [AHA: Pelacarsen cuts lipoprotein(a) levels but does not lower risk for major adverse cardiovascular events](https://medicalxpress.com/news/2026-11-aha-pelacarsen-lipoproteina-major-adverse.html) — Medical Xpress - latest medical and health news stories, 2026-11-12

Tags: lipoprotein(a), cardiovascular, pelacarsen, antisense oligonucleotide, clinical trial

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science